ZVA explains that the experts of the Latvian State Council of Immunization recommend the use of AstraZeneca vaccine for the prevention of Covid-19 disease in people of all ages from 18 years of age.
The Agency states that, although data from clinical trials on the effects of the vaccine in humans over 65 years of age are not yet sufficient, protection is expected given the immune response observed in this age group and experience with other vaccines. “As reliable safety data have been obtained in this patient population, EZA scientists believe that the vaccine can also be used in older adults. More information is expected from ongoing studies involving the majority of the elderly,” he said. ZVA.
Vaccination against Covid-19 is launched in Latvia
–
–
–
+17 See more
–
–
At the same time, the overall vaccine has shown approximately 60% efficacy in clinical trials.
The MAH also mentioned that people who had already had Covid-19 had also been studied in clinical trials and that no additional side effects were seen, but due to the small number of people (345 people), not enough data were available to draw conclusions about the specific condition. effectiveness of the vaccine in people who have already had Covid-19, but the effects are also expected in this group.
The effect of vaccination with AstraZeneca on the spread of Covid-19 virus in the community is currently unknown – the extent to which vaccinated individuals may be able to carry and spread the virus is not yet known. These aspects were planned to be evaluated in the clinical trial, but not enough data were collected to draw conclusions. It is expected that such information will be obtained in the post-registration period, according to ZVA.
The first vaccines developed by Pfizer and BioNTech have reached Latvia
–
–
–
+14 See more
–
–
The most common side effects with the vaccine are pain and tenderness at the injection site, headache, tiredness, muscle aches, feeling generally unwell, chills, fever, joint pain and nausea. These side effects affected more than one in ten people vaccinated, but vomiting and diarrhea were seen in less than one in ten people. On the other hand, less than 1 in 100 people developed reduced appetite, dizziness, sweating, abdominal pain and rash. Allergic reactions have been reported in vaccinated individuals.
As the vaccine manufactured by AstraZeneca is recommended for registration subject to additional conditions, the company that distributes the vaccine will need to continue to provide the results of ongoing clinical trials. These studies, as well as additional studies, will provide information on the duration of protection provided by the vaccine, its protection against new strains of the virus, its effectiveness in preventing severe Covid-19, its effectiveness in the elderly, immunocompromised people, children and pregnant women, and asymptomatic disease. .
Latvia receives the first manufacturer “Moderna” vaccines against Covid-19
–
–
–
+27 See more
–
–
The Agency notes that, in addition, independent studies of Covid-19 vaccines organized by the European Union (EU) authorities will provide more information on the long-term safety and benefits of the vaccine for the general public. The company will also carry out studies to provide additional evidence of the pharmaceutical quality and testing of the vaccine, further increasing production.
It has already been reported that the EC approved AstraZeneca vaccines for use in the EU on Friday, January 29.
The EZA on Friday recommended that the EC approve the AstraZeneca vaccine for all people over the age of 18, saying it thought it was also effective in the elderly.
EZA approval was expected, but there were questions about whether it would follow the example of Germany, which did not recommend it to people over 65.
“With today’s recommendation, we are further expanding the range of vaccines available in EU countries to bring the pandemic under control,” EZA Director Emera Cook told a news conference at EZA’s headquarters in Amsterdam. “None of them are a magic wand in themselves, but together they give us the tools and opportunities we need.”
The vaccine, developed by AstraZeneca and the University of Oxford, has shown 60% effectiveness in various clinical trials, according to an EZA statement. AstraZeneca has advocated the use of the vaccine in all age groups, and the company is also supported by the United Kingdom, which extends vaccines to the elderly.
The EU has so far approved two Covid-19 vaccines, one developed by the US company Pfizer and the German company BioNTech, and the other by the US company Moderna.
The vaccine, developed by AstraZeneca and the University of Oxford, is cheaper to produce than its competitors, easier to store and transport.
AstraZeneca has warned that deliveries of Covid-19 vaccine to the EU will be delayed due to declining production.
With the approval of the AstraZeneca vaccine for use in the EU, Latvia has taken a step closer to receiving the first deliveries of this manufacturer’s vaccines in February, as currently planned, Oskars Šneiders, a representative of the Ministry of Health (MoW), told LETA.
“AstraZeneca is the vaccine that is emphasized in the Latvian vaccine portfolio, so this decision is very important for us,” the VM representative explained. As previously reported, this vaccine differs from the others in its relatively low cost and easier storage and transportation.
According to the information provided by the manufacturer to the National Health Service, AstraZeneca initially promised to supply 423,957 doses of vaccine to Latvia in the first quarter of this year, but now, according to the vaccination plan approved by the government yesterday, the amount has dropped to 108,791.
Others are currently reading
Creeping – weed, but with healing power
–
–
“He saved lives” – an active rat named Magava ends his active career
–
–
–
The lowest ever activity was registered in municipal elections
